This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment for participants with previously untreated locally advanced non-small cell lung cancer (NSCLC)
Aim of the study
The study is designed to assess the effect, whether positive or negative, of the administration of Tecentriq® (atezolizumab) and tiragolumab with or without chemotherapy in patients whose lung cancer can be operated on. The aim is to find out whether and/or for how long these drugs can prevent a relapse of the disease.
Who can take part?
Patients with previously untreated locally advanced, non-small cell and resectable stage II, IIIA or selected IIIB lung cancer
Procedure
You will be assigned to one of the following treatment groups based on the amount of so-called PD-L1 (programmed-death ligand 1, a special receptor on tumor cells that is important for interaction with cells of the immune system) on the surface of your tumor:- Patients in cohort A (high PD-L1 status) will receive Tecentriq® and tiragolumab (as an intravenous infusion) every 3 weeks for a period of 12 weeks prior to surgery. - Patients in Cohort B (low PD-L1 status) will receive Tecentriq® and tiragolumab (as an intravenous infusion) in combination with platinum-based chemotherapy every 3 weeks for up to 12 weeks prior to surgery.
Compensation
None
Original study name
An open-label, multicenter phase II study to evaluate the safety and efficacy of neoadjuvant and adjuvant tiragolumab plus atezolizumab with or without platinum-based chemotherapy in patients with previously untreated stage II, IIIA or selected IIIB locally advanced, non-small cell and resectable lung cancer
BASEC number
2020-02596
Financial support from
Roche